These commenters noted that many rural facilities operate with limited staff, infrastructure, and technological resources, which can make implementation and reporting of complex eCQMs especially challenging
The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently
Once there, it binds to GHRH receptors all over the body, but especially on the pituitary gland
Genetic variants do not determine treatment outcome but may inform personalization discussions